CLRB 8-K: SEC filing
Cellectar Biosciences
Filed with the SEC on · accession 0001104659-26-124790
CLRB filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Cellectar Biosciences reported its third quarter 2026 financial results and provided a corporate update via a press release furnished on Form 8-K.
Key details
✦ Ask GOAX AI about this filing — what it means for CLRB, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CLRB?
Click hereFrequently asked questions
What did CLRB file with the SEC on Nov 10, 2026?
CLRB filed a 8-K (SEC filing). Cellectar Biosciences reported its third quarter 2026 financial results and provided a corporate update via a press release furnished on Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other CLRB SEC filings
Get alerts when CLRB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days